<DOC>
	<DOCNO>NCT01184079</DOCNO>
	<brief_summary>The investigator propose randomize , open label trial immunogenicity HPV vaccine among male 18-24 year old , compare on-time administration third dose delayed administration third dose . All participant would receive first second dos accord schedule . They would randomize either Dose 3 6 month Dose 3 12 month . Hypothesis : The Geometric mean titer 12 month test group ( T ) non-inferior usual timing control group ( C ) : H0 : δ ≤ −δ0 versus H1 : δ &gt; −δ0 δ = log ( GMTT ) − log ( GMTC ) δ0 pre-specified non-inferiority margin</brief_summary>
	<brief_title>Randomized Trial Alternative HPV Vaccination Schedules Males University Setting</brief_title>
	<detailed_description>1 . Specific Aims Overview : The investigator propose randomize , open label trial HPV vaccine among male 18-24 year old , compare on-time administration third dose delayed administration third dose . All participant would receive first second dos accord schedule . They would randomize either Dose 3 6 month Dose 3 12 month . Blood would draw titer twice participant : pre-dose 1 one month post Dose 3 . No cytology study DNA study conduct . 1.1 Aims : 1 . Determine delay third dose immunologically non-inferior standard administration schedule ( 1 month post-dose 3 ) . 2 . Determine side effect profile delay third dose , comparison standard schedule . 3 . Determine preference compliance men time third dose . 1.2 Hypothesis non- inferiority : The GMTs test group ( T ) non-inferior usual timing control group ( C ) : H0 : δ ≤ −δ0 versus H1 : δ &gt; −δ0 δ = log ( GMTT ) − log ( GMTC ) δ0 pre-specified non-inferiority margin .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males age 1826 Hospitalization within past year Previous HPV vaccination &gt; /=5 sexual partner ( i.e. , insertive intercourse ) No drug study within 30 day propose HPV vaccination History genital wart Immunosuppression Other vaccine within 8 day propose HPV vaccination Hypersensitivity yeast HPV vaccine component Known autoimmune disorder Receipt immunoglobulins blood product within 90 day enrollment ( may defer 90 day complete ) Serious Adverse Reaction HPV vaccine</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>human papillomavirus vaccine L1 , type 6,11,16,18</keyword>
	<keyword>HPV Vaccines</keyword>
	<keyword>HPV L1 vaccine , quadrivalent 6,11,16,18</keyword>
</DOC>